Interleukin-20 as a target in psoriasis treatment

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 368-381

  Stenderup, Karin ^a   Rosada, Cecilia ^a   Worsaae, Anne ^b   Clausen, Jes Thorn ^b   Dam, Tomas Norman ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c ROSKILDE HOSPITAL   (Denmark)

Author keywords

Human keratinocytes; Interleukin 20; PBMCs; Psoriasis; Skin

Indexed keywords

CYTOKINE; INTERLEUKIN 20; INTERLEUKIN RECEPTOR;

ANGIOGENESIS; CELL CULTURE; CELL PROLIFERATION; CELL STIMULATION; CHEMOTAXIS; CONFERENCE PAPER; EPIDERMIS; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATORY DISEASE; KERATINOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PSORIASIS; SIGNAL TRANSDUCTION; SKIN; SKINFOLD; TARGET CELL;

MUS MUSCULUS;

EID: 34948857446     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.039     Document Type: Conference Paper

References (57)

1. DAVIDSSON, S., K. BLOMQVIST, L. MOLIN, et al. 2005. Lifestyle of Nordic people with psoriasis. Int J. Dermatol. 44: 378-383.
2. ZACHARIAE, R., H. ZACHARIAE, K. BLOMQVIST, et al. 2004. Self-reported stress reactivity and psoriasis-related stress of Nordic psoriasis sufferers. J. Eur. Acad. Dermatol. Venereol. 18: 27-36.
3. BOEHNCKE, W.H., J. PRINZ & A.B. GOTTLIEB. 2006. Biologic therapies for psoriasis. A systematic review. J. Rheumatol. 33: 1447-1451.
4. STERRY, W., J. BARKER, W.H. BOEHNCKE, et al. 2004. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br. J. Dermatol. 151(Suppl 69): 3-17.
5. VAN DE KERKHOF, P.C. & K. KRAGBALLE. 2005. Recommendations for the topical treatment of psoriasis. J. Eur. Acad. Dermatol. Venereol. 19: 495-499.
6. BLUMBERG, H., D. CONKLIN, W.F. XU, et al. 2001. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104: 9-19.
7. GALLAGHER, G., H. DICKENSHEETS, J. ESKDALE, et al. 2000. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun. 1: 442-450.
8. DUMOUTIER, L., R.E. VAN, G. AMEYE, et al. 2000. IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun. 1: 488-494.
9. JIANG, H., Z.Z. SU, J.J. LIN, et al. 1996. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc. Natl. Acad. Sci. USA 93: 9160-9165.
10. KNAPPE, A., S. HOR, S. WITTMANN & H. FICKENSCHER. 2000. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J. Virol. 74: 3881-3887.
11. HEUZE-VOURC'H, N., M. LIU, H. DALWADI, et al. 2005. IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression. Biochem. Biophys. Res. Commun. 333: 470-475.
12. HSIEH, M.Y., W.Y. CHEN, M.J. JIANG, et al. 2006. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun. 7: 234-242.
13. HSU, Y.H., H.H. LI, M.Y. HSIEH, et al. 2006. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum. 54: 2722-2733.
14. WANG, F., E. LEE, M.A. LOWES, et al. 2006. Prominent production of IL-20 by CD68(+)/CD11 c(+) myeloid-derived cells in psoriasis: gene regulation and cellular effects. J. Invest. Dermatol. 126: 1590-1599.
15. OTKJAER, K., K. KRAGBALLE, A.T. FUNDING, et al. 2005. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br. J. Dermatol. 153: 911-918.
16. WEI, C.C., W.Y. CHEN, Y.C. WANG, et al. 2005. Detection of IL-20 and its receptors on psoriatic skin. Clin. Immunol. 117: 65-72.
17. RøMER, J., E. HASSELAGER, P.L. NORBY, et al. 2003. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol. J. Invest. Dermatol. 121: 1306-1311.
18. OGILVIE, A.L., M. LUFTL, C. ANTONI, et al. 2006. Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha. Int. J. Immunopathol. Pharmacol. 19: 271-278.
19. GHORESCHI, K., P. THOMAS, S. BREIT, et al. 2003. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9: 40-46.
20. GUDJONSSON, J.E., A. JOHNSTON, H. S IGMUNDSDOTTIR & H. VALDIMARSSON. 2004. Immunopathogenic mechanisms in psoriasis. Clin. Exp. Immunol. 135: 1-8.
21. NICKOLOFF, B.J. & F.O. NESTLE. 2004. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113: 1664-1675.
22. PRINZ, J.C. 2004. Disease mimicry - a pathogenetic concept for T cell-mediated autoimmune disorders triggered by molecular mimicry? Autoimmun. Rev. 3: 10-15.
23. VALDIMARSSON, H., B.S. BAKER, I. JONSDOTTIR, et al. 1995. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol. Today 16: 145-149.
24. ALLEN, M.H., H. AMEEN, C. VEAL, et al. 2005. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J. Invest. Dermatol. 124: 103-106.
25. NAIR, R.P., P.E. STUART, I. NISTOR, et al. 2006. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am. J. Hum. Genet. 78: 827-851.
26. AUSTIN, L.M., M. OZAWA, T. KIKUCHI, et al. 1999. The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferongamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J. Invest. Dermatol. 113: 752-759.
27. BOS, J.D., M.A. DERIE, M.B. TEUNISSEN & G. PISKIN. 2005. Psoriasis: dysregulation of innate immunity. Br. J. Dermatol. 152: 1098-1107.
28. BOYMAN, O., C. CONRAD, G. TONEL, et al. 2007. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol. 28: 51-57.
29. DAM, T.N., S. KANG, B.J. NICKOLOFF & J.J. VOORHEES. 1999. 1alpha,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J. Invest. Dermatol. 113: 1082-1089.
30. KRUEGER, G.G. & K.P. CALLIS. 2003. Development and use of alefacept to treat psoriasis. J. Am. Acad. Dermatol. 49: S87-S97.
31. KRUEGER, J.G. 2002. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46: 1-23.
32. SANO, S., K.S. CHAN, S. CARBAJAL, et al. 2005. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11: 43-49.
33. SUGIYAMA, H., R. GYULAI, E. TOICHI, et al. 2005. Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 174: 164-173.
34. VILLADSEN, L.S., J. SCHUURMAN, F. BEURSKENS, et al. 2003. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J. Clin. Invest. 112: 1571-1580.
35. KOTENKO, S.V. 2002. The family of IL-10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev. 13: 223-240.
36. LIAO, S.C., Y.C. CHENG, Y.C. WANG, et al. 2004. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J. Immunol. 173: 6712-6718.
37. PLETNEV, S., E. MAGRACHEVA, S. KOZLOV, et al. 2003. Characterization of the recombinant extracellular domains of human interleukin-20 receptors and their complexes with interleukin-19 and interleukin-20. Biochemistry 42: 12617-12624.
38. OTKJAER, K., K. KRAGBALLE, C. JOHANSEN, et al. 2007. IL-20 gene expression is induced by IL-1beta through mitogen-activated protein kinase and NF-kappaB-dependent mechanisms. J. Invest. Dermatol. 127: 1326-1336.
39. RICH, B.E. & T.S. KUPPER. 2001. Cytokines: IL-20 - a new effector in skin inflammation. Curr. Biol. 11: R531-R534.
40. KUNZ, S., K. WOLK, E. WITTE, et al. 2006. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp. Dermatol. 15: 991-1004.
41. HSING, C.H., C.L. HO, L.Y. CHANG, et al. 2006. Tissue microarray analysis of interleukin-20 expression. Cytokine 35: 44-52.
42. MENON, R., L. ISMAIL, D. ISMAIL, et al. 2006. Human fetal membrane expression of IL-19 and IL-20 and its differential effect on inflammatory cytokine production. J. Matern. Fetal Neonatal Med. 19: 209-214.
43. HUNT, D.W., W.A. BOIVIN, L.A. FAIRLEY, et al. 2006. Ultraviolet B light stimulates interleukin-20 expression by human epithelial keratinocytes. Photochem. Photobiol. 82: 1292-1300.
44. WOLK, K., S. KUNZ, K. ASADULLAH & R. SABAT. 2002. Cutting edge: immune cells as sources and targets of the IL-10 family members? J. Immunol. 168: 5397-5402.
45. NAGALAKSHMI, M.L., E. MURPHY, T. MCCLANAHAN & M.R. DE WAAL. 2004. Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization. Int. Immunopharmacol. 4: 577-592.
46. DUMOUTIER, L., C. LEEMANS, D. LEJEUNE, et al. 2001. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J. Immunol. 167: 3545-3549.
47. FICKENSCHER, H., S. HOR, H. KUPERS, et al. 2002. The interleukin-10 family of cytokines. Trends Immunol. 23: 89-96.
48. PARRISH-NOVAK, J., W. XU, T. BRENDER, et al. 2002. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J. Biol. Chem. 277: 47517-47523.
49. BONIFACE, K., J.C. LECRON, F.X. BERNARD, et al. 2005. Keratinocytes as targets for interleukin-10-related cytokines: a putative role in the pathogenesis of psoriasis. Eur. Cytokine Netw. 16: 309-319.
50. SA, S.M., P.A. VALDEZ, J. WU, et al. 2007. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 178: 2229-2240.
51. WEGENKA, U.M., N. DIKOPOULOS, J. REIMANN, et al. 2007. The murine liver is a potential target organ for IL-19, IL-20 and IL-24: type I interferons and LPS regulate the expression of IL-20R2. J. Hepatol. 46: 257-265.
52. HOSOI, T., S. WADA, S. SUZUKI, et al. 2004. Bacterial endotoxin induces IL-20 expression in the glial cells. Brain Res. Mol. Brain Res. 130: 23-29.
53. LIU, L., C. DING, W. ZENG, et al. 2003. Selective enhancement of multipotential hematopoietic progenitors in vitro and in vivo by IL-20. Blood 102: 3206-3209.
54. KINGO, K., S. KOKS, T. NIKOPENSIUS, et al. 2004. Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes Immun. 5: 117-121.
55. KOKS, S., K. KINGO, R. RATSEP, et al. 2004. Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis. Genes Immun. 5: 662-667.
56. KOKS, S., K. KINGO, K. VABRIT, et al. 2005. Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun. 6: 407-415.
57. CHEN, W.Y., B.C. CHENG, M.J. JIANG, et al. 2006. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 26: 2090-2095.